Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Hematology
Link
http://link.springer.com/content/pdf/10.1007/s12288-019-01167-w.pdf
Reference20 articles.
1. (1997) A clinical evaluation of the international lymphoma study group classification of non-Hodgkin’s lymphoma. Blood 89(11):3909
2. World Cancer Report (2014) International agency for research on cancer. Accessed July 2014
3. Coiffier B, Thieblemont C, Van Den Neste E et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 116(12):2040–2045
4. Pfreundschuh M, Kuhnt E, Trumper L et al (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12(11):1013–1022
5. Bosch X, Ramos-Casals M, Khamashta MA (2013) Drugs targeting B-cells in autoimmune diseases. Springer Science & Business Media, Berlin, pp 1–4
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma;Oncology and Therapy;2024-06-03
2. Assessment of Clinical Benefit, Cost and Uptake of Biosimilars Versus Reference Biologics in Immune-Mediated Inflammatory Diseases in China;2024
3. Clinical Benefit, Price, and Uptake for Cancer Biosimilars vs Reference Drugs in China;JAMA Network Open;2023-10-12
4. Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era;Frontiers in Oncology;2023-10-03
5. Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma;Asian Journal of Surgery;2023-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3